| 1 |
Kuwana, Y., Asakura, Y., Utsunomiya, N., Nakanishi, M., Arata, Y., Itoh, S., Nagase, F. and Kurosawa, Y. (1987) Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem. Biophys. Res. Commun. 149, 960-968.
DOI
|
| 2 |
Leach, D. R., Krummel, M. F. and Allison, J. P. (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736.
DOI
|
| 3 |
Lee, L., Wang, R. F., Wang, X., Mixon, A., Johnson, B. E., Rosenberg, S. A. and Schrump, D. S. (1999) NY-ESO-1 may be a potential target for lung cancer immunotherapy. Cancer J. Sci. Am. 5, 20-25.
|
| 4 |
Liu, Y. and Zheng, P. (2020) Preserving the CTLA-4 checkpoint for safer and more effective cancer immunotherapy. Trends Pharmacol. Sci. 41, 4-12.
DOI
|
| 5 |
Maher, J., Brentjens, R. J., Gunset, G., Riviere, I. and Sadelain, M. (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat. Biotechnol. 20, 70-75.
DOI
|
| 6 |
Majzner, R. G., Theruvath, J. L., Nellan, A., Heitzeneder, S., Cui, Y., Mount, C. W., Rietberg, S. P., Linde, M. H., Xu, P., Rota, C., Sotillo, E., Labanieh, L., Lee, D. W., Orentas, R. J., Dimitrov, D. S., Zhu, Z., Croix, B. S., Delaidelli, A., Sekunova, A., Bonvini, E., Mitra, S. S., Quezado, M. M., Majeti, R., Monje, M., Sorensen, P. H. B., Maris, J. M. and Mackall, C. L. (2019) CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin. Cancer Res. 25, 2560-2574.
DOI
|
| 7 |
Huang, L. Q., Brasseur, F., Serrano, A., De Plaen, E., van der Bruggen, P., Boon, T. and Van Pel, A. (1999) Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma. J. Immunol. 162, 6849-6854.
DOI
|
| 8 |
Hung, C. F., Xu, X., Li, L., Ma, Y., Jin, Q., Viley, A., Allen, C., Natarajan, P., Shivakumar, R., Peshwa, M. V. and Emens, L. A. (2018) Development of anti-human mesothelin-targeted chimeric antigen receptor messenger RNA-transfected peripheral blood lymphocytes for ovarian cancer therapy. Hum. Gene Ther. 29, 614-625.
DOI
|
| 9 |
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T. and Minato, N. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U.S.A. 99, 12293-12297.
DOI
|
| 10 |
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., Rodig, S. J., Chapuy, B., Ligon, A. H., Zhu, L., Grosso, J. F., Kim, S. Y., Timmerman, J. M., Shipp, M. A. and Armand, P. (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311-319.
DOI
|
| 11 |
Aung, P. P., Liu, Y. C., Ballester, L. Y., Robbins, P. F., Rosenberg, S. A. and Lee, C. C. (2014) Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma. Hum. Pathol. 45, 259-267.
DOI
|
| 12 |
Bielamowicz, K., Fousek, K., Byrd, T. T., Samaha, H., Mukherjee, M., Aware, N., Wu, M. F., Orange, J. S., Sumazin, P., Man, T. K., Joseph, S. K., Hegde, M. and Ahmed, N. (2018) Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. NeuroOncol. 20, 506-518.
|
| 13 |
Rosenthal, M. A., Balana, C., van Linde, M. E., Sayehli, C., Fiedler, W. M., Wermke, M., Massard, C., Mellinghoff, I. K., Khasraw, M., Ang, A., Rasmussen, E., Kast, J., Stienen, S. and Cloughesy, T. F. (2019) ATIM-49 (LTBK-01). AMG 596, a novel anti-EGFRvIII bispecific T cell engager (BITE(®)) molecule for the treatment of glioblastoma (GBM): planned interim analysis in recurrent GBM (RGBM). Neuro-Oncol. 21, vi283.
|
| 14 |
Ghorashian, S., Kramer, A. M., Onuoha, S., Wright, G., Bartram, J., Richardson, R., Albon, S. J., Casanovas-Company, J., Castro, F., Popova, B., Villanueva, K., Yeung, J., Vetharoy, W., Guvenel, A., Wawrzyniecka, P. A., Mekkaoui, L., Cheung, G. W., Pinner, D., Chu, J., Lucchini, G., Silva, J., Ciocarlie, O., Lazareva, A., Inglott, S., Gilmour, K. C., Ahsan, G., Ferrari, M., Manzoor, S., Champion, K., Brooks, T., Lopes, A., Hackshaw, A., Farzaneh, F., Chiesa, R., Rao, K., Bonney, D., Samarasinghe, S., Goulden, N., Vora, A., Veys, P., Hough, R., Wynn, R., Pule, M. A. and Amrolia, P. J. (2019) Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat. Med. 25, 1408-1414.
DOI
|
| 15 |
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., Morton, K. E., Laurencot, C. M., Steinberg, S. M., White, D. E. and Dudley, M. E. (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using Tcell transfer immunotherapy. Clin. Cancer Res. 17, 4550-4557.
DOI
|
| 16 |
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., Herati, R. S., Mansfield, K. D., Patsch, D., Amaravadi, R. K., Schuchter, L. M., Ishwaran, H., Mick, R., Pryma, D. A., Xu, X., Feldman, M. D., Gangadhar, T. C., Hahn, S. M., Wherry, E. J., Vonderheide, R. H. and Minn, A. J. (2015) Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373-377.
DOI
|
| 17 |
Rapoport, A. P., Stadtmauer, E. A., Binder-Scholl, G. K., Goloubeva, O., Vogl, D. T., Lacey, S. F., Badros, A. Z., Garfall, A., Weiss, B., Finklestein, J., Kulikovskaya, I., Sinha, S. K., Kronsberg, S., Gupta, M., Bond, S., Melchiori, L., Brewer, J. E., Bennett, A. D., Gerry, A. B., Pumphrey, N. J., Williams, D., Tayton-Martin, H. K., Ribeiro, L., Holdich, T., Yanovich, S., Hardy, N., Yared, J., Kerr, N., Philip, S., Westphal, S., Siegel, D. L., Levine, B. L., Jakobsen, B. K., Kalos, M. and June, C. H. (2015) NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat. Med. 21, 914-921.
DOI
|
| 18 |
Riley, R. S., June, C. H., Langer, R. and Mitchell, M. J. (2019) Delivery technologies for cancer immunotherapy. Nat. Rev. Drug Discov. 18, 175-196.
DOI
|
| 19 |
Robbins, P. F., Kassim, S. H., Tran, T. L., Crystal, J. S., Morgan, R. A., Feldman, S. A., Yang, J. C., Dudley, M. E., Wunderlich, J. R., Sherry, R. M., Kammula, U. S., Hughes, M. S., Restifo, N. P., Raffeld, M., Lee, C. C., Li, Y. F., El-Gamil, M. and Rosenberg, S. A. (2015) A pilot trial using lymphocytes genetically engineered with an NYESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21, 1019-1027.
DOI
|
| 20 |
Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C. and Seipp, C. A. (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319, 1676-1680.
DOI
|
| 21 |
Porter, D. L., Kalos, M., Zheng, Z., Levine, B. and June, C. (2011a) Chimeric antigen receptor therapy for B-cell malignancies. J. Cancer 2, 331-332.
DOI
|
| 22 |
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J. J., Butler, M. O., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R. R., Smylie, M., Meyer, N., Mortier, L., Atkins, M. B., Long, G. V., Bhatia, S., Lebbe, C., Rutkowski, P., Yokota, K., Yamazaki, N., Kim, T. M., de Pril, V., Sabater, J., Qureshi, A., Larkin, J. and Ascierto, P. A.; CheckMate 238 Collaborators (2017) Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 377, 1824-1835.
DOI
|
| 23 |
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., Chen, C., Olive, O., Carter, T. A., Li, S., Lieb, D. J., Eisenhaure, T., Gjini, E., Stevens, J., Lane, W. J., Javeri, I., Nellaiappan, K., Salazar, A. M., Daley, H., Seaman, M., Buchbinder, E. I., Yoon, C. H., Harden, M., Lennon, N., Gabriel, S., Rodig, S. J., Barouch, D. H., Aster, J. C., Getz, G., Wucherpfennig, K., Neuberg, D., Ritz, J., Lander, E. S., Fritsch, E. F., Hacohen, N. and Wu, C. J. (2017) An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217-221.
DOI
|
| 24 |
Palmer, D. C., Guittard, G. C., Franco, Z., Crompton, J. G., Eil, R. L., Patel, S. J., Ji, Y., Van Panhuys, N., Klebanoff, C. A., Sukumar, M., Clever, D., Chichura, A., Roychoudhuri, R., Varma, R., Wang, E., Gattinoni, L., Marincola, F. M., Balagopalan, L., Samelson, L. E. and Restifo, N. P. (2015) Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J. Exp. Med. 212, 2095-2113.
DOI
|
| 25 |
Klinger, M., Benjamin, J., Kischel, R., Stienen, S. and Zugmaier, G. (2016) Harnessing T cells to fight cancer with BiTE(R) antibody constructs--past developments and future directions. Immunol. Rev. 270, 193-208.
DOI
|
| 26 |
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J. J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., Smylie, M., Dummer, R., Hill, A., Hogg, D., Haanen, J., Carlino, M. S., Bechter, O., Maio, M., Marquez-Rodas, I., Guidoboni, M., McArthur, G., Lebbe, C., Ascierto, P. A., Long, G. V., Cebon, J., Sosman, J., Postow, M. A., Callahan, M. K., Walker, D., Rollin, L., Bhore, R., Hodi, F. S. and Larkin, J. (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345-1356.
DOI
|
| 27 |
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B. P., Simon, P., Lower, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrors, B., Omokoko, T., Vormehr, M., Albrecht, C., Paruzynski, A., Kuhn, A. N., Buck, J., Heesch, S., Schreeb, K. H., Muller, F., Ortseifer, I., Vogler, I., Godehardt, E., Attig, S., Rae, R., Breitkreuz, A., Tolliver, C., Suchan, M., Martic, G., Hohberger, A., Sorn, P., Diekmann, J., Ciesla, J., Waksmann, O., Bruck, A. K., Witt, M., Zillgen, M., Rothermel, A., Kasemann, B., Langer, D., Bolte, S., Diken, M., Kreiter, S., Nemecek, R., Gebhardt, C., Grabbe, S., Holler, C., Utikal, J., Huber, C., Loquai, C. and Tureci, O. (2017) Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222-226.
DOI
|
| 28 |
Schlothauer, T., Herter, S., Koller, C. F., Grau-Richards, S., Steinhart, V., Spick, C., Kubbies, M., Klein, C., Umana, P. and Mossner, E. (2016) Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng. Des. Sel. 29, 457-466.
DOI
|
| 29 |
Ishiguro, T., Sano, Y., Komatsu, S. I., Kamata-Sakurai, M., Kaneko, A., Kinoshita, Y., Shiraiwa, H., Azuma, Y., Tsunenari, T., Kayukawa, Y., Sonobe, Y., Ono, N., Sakata, K., Fujii, T., Miyazaki, Y., Noguchi, M., Endo, M., Harada, A., Frings, W., Fujii, E., Nanba, E., Narita, A., Sakamoto, A., Wakabayashi, T., Konishi, H., Segawa, H., Igawa, T., Tsushima, T., Mutoh, H., Nishito, Y., Takahashi, M., Stewart, L., ElGabry, E., Kawabe, Y., Ishigai, M., Chiba, S., Aoki, M., Hattori, K. and Nezu, J. (2017) An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. Sci. Transl. Med. 9, eaal4291.
DOI
|
| 30 |
Chen, R., Zinzani, P. L., Lee, H. J., Armand, P., Johnson, N. A., Brice, P., Radford, J., Ribrag, V., Molin, D., Vassilakopoulos, T. P., Tomita, A., von Tresckow, B., Shipp, M. A., Lin, J., Kim, E., Nahar, A., Balakumaran, A. and Moskowitz, C. H. (2019) Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood 134, 1144-1153.
|
| 31 |
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. and June, C. H. (2011b) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733.
DOI
|
| 32 |
Ramachandran, I., Lowther, D. E., Dryer-Minnerly, R., Wang, R., Fayngerts, S., Nunez, D., Betts, G., Bath, N., Tipping, A. J., Melchiori, L., Navenot, J. M., Glod, J., Mackall, C. L., D'Angelo, S. P., Araujo, D. M., Chow, W. A., Demetri, G. D., Druta, M., Van Tine, B. A., Grupp, S. A., Abdul Razak, A. R., Wilky, B., Iyengar, M., Trivedi, T., Winkle, E. V., Chagin, K., Amado, R., Binder, G. K. and Basu, S. (2019) Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. J. Immunother. Cancer 7, 276.
DOI
|
| 33 |
Green, E. W., Bunse, L., Bozza, M., Sanghvi, K. and Platten, M. (2019) TCR validation toward gene therapy for cancer. Methods Enzymol. 629, 419-441.
DOI
|
| 34 |
Grosso, J. F. and Jure-Kunkel, M. N. (2013) CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 13, 5.
|
| 35 |
Hargadon, K. M., Johnson, C. E. and Williams, C. J. (2018) Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int. Immunopharmacol. 62, 29-39.
DOI
|
| 36 |
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., Milone, M. C., Levine, B. L. and June, C. H. (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518.
DOI
|
| 37 |
Hummel, H. D., Kufer, P., Grullich, C., Seggewiss-Bernhardt, R., Deschler-Baier, B., Chatterjee, M., Goebeler, M. E., Miller, K., de Santis, M., Loidl, W., Dittrich, C., Buck, A., Lapa, C., Thurner, A., Wittemer-Rump, S., Koca, G., Boix, O., Docke, W. D., Finnern, R., Kusi, H., Ajavon-Hartmann, A., Stienen, S., Sayehli, C. M., Polat, B. and Bargou, R. C. (2021) Pasotuxizumab, a BiTE(®) immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings. Immunotherapy 13, 125-141.
DOI
|
| 38 |
Reck, M., Rodriguez-Abreu, D., Robinson, A. G., Hui, R., Csoszi, T., Fulop, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O'Brien, M., Rao, S., Hotta, K., Leiby, M. A., Lubiniecki, G. M., Shentu, Y., Rangwala, R. and Brahmer, J. R.; KEYNOTE-024 Investigators (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823-1833.
DOI
|
| 39 |
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T. and Sakaguchi, S. (2008) CTLA-4 control over Foxp3+ regulatory T cell function. Science 322, 271-275.
DOI
|
| 40 |
Halliday, G. M., Patel, A., Hunt, M. J., Tefany, F. J. and Barnetson, R. S. (1995) Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells. World J. Surg. 19, 352-358.
DOI
|
| 41 |
Hilal, T. and Prasad, V. (2018) Eliminating MRD - FDA approval of blinatumomab for B-ALL in complete remission. Nat. Rev. Clin. Oncol. 15, 727-728.
DOI
|
| 42 |
Imai, C., Mihara, K., Andreansky, M., Nicholson, I. C., Pui, C. H., Geiger, T. L. and Campana, D. (2004) Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18, 676-684.
DOI
|
| 43 |
Karapetyan, A. R., Chaipan, C., Winkelbach, K., Wimberger, S., Jeong, J. S., Joshi, B., Stein, R. B., Underwood, D., Castle, J. C., van Dijk, M. and Seibert, V. (2019) TCR fingerprinting and off-target peptide identification. Front. Immunol. 10, 2501.
DOI
|
| 44 |
Schultz-Thater, E., Piscuoglio, S., Iezzi, G., Le Magnen, C., Zajac, P., Carafa, V., Terracciano, L., Tornillo, L. and Spagnoli, G. C. (2011) MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies. Int. J. Cancer 129, 1137-1148.
DOI
|
| 45 |
Bendell, J. C., Fong, L., Stein, M. N., Beer, T. M., Ross, A., Gao, X., Weitzman, A., Austin, R., Ganti, V., Law, C., Lemon, B., Wesche, H. and De Bono, J. S. (2020) First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 38, 5552.
DOI
|
| 46 |
Brocker, T. (2000) Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood 96, 1999-2001.
DOI
|
| 47 |
Stein, A. S., Schiller, G., Benjamin, R., Jia, C., Zhang, A., Zhu, M., Zimmerman, Z. and Topp, M. S. (2019) Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. Ann. Hematol. 98, 159-167.
DOI
|
| 48 |
Song, S., Han, M., Zhang, H., Wang, Y. and Jiang, H. (2013) Full screening and accurate subtyping of HLA-A*02 alleles through group-specific amplification and mono-allelic sequencing. Cell. Mol. Immunol. 10, 490-496.
DOI
|
| 49 |
Tan, M. P., Gerry, A. B., Brewer, J. E., Melchiori, L., Bridgeman, J. S., Bennett, A. D., Pumphrey, N. J., Jakobsen, B. K., Price, D. A., Ladell, K. and Sewell, A. K. (2015) T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells. Clin. Exp. Immunol. 180, 255-270.
DOI
|
| 50 |
Wu, J., Fu, J., Zhang, M. and Liu, D. (2015) Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J. Hematol. Oncol. 8, 104.
DOI
|
| 51 |
Zacharakis, N., Chinnasamy, H., Black, M., Xu, H., Lu, Y. C., Zheng, Z., Pasetto, A., Langhan, M., Shelton, T., Prickett, T., Gartner, J., Jia, L., Trebska-McGowan, K., Somerville, R. P., Robbins, P. F., Rosenberg, S. A., Goff, S. L. and Feldman, S. A. (2018) Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat. Med. 24, 724-730.
DOI
|
| 52 |
Zehn, D., Lee, S. Y. and Bevan, M. J. (2009) Complete but curtailed T-cell response to very low-affinity antigen. Nature 458, 211-214.
DOI
|
| 53 |
Zhang, Y., Du, X., Liu, M., Tang, F., Zhang, P., Ai, C., Fields, J. K., Sundberg, E. J., Latinovic, O. S., Devenport, M., Zheng, P. and Liu, Y. (2019) Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy. Cell Res. 29, 609-627.
DOI
|
| 54 |
D'Ippolito, E., Schober, K., Nauerth, M. and Busch, D. H. (2019) T cell engineering for adoptive T cell therapy: safety and receptor avidity. Cancer Immunol. Immunother. 68, 1701-1712.
DOI
|
| 55 |
Motzer, R. J., Tannir, N. M., McDermott, D. F., Aren Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthelemy, P., Porta, C., George, S., Powles, T., Donskov, F., Neiman, V., Kollmannsberger, C. K., Salman, P., Gurney, H., Hawkins, R., Ravaud, A., Grimm, M. O., Bracarda, S., Barrios, C. H., Tomita, Y., Castellano, D., Rini, B. I., Chen, A. C., Mekan, S., McHenry, M. B., Wind-Rotolo, M., Doan, J., Sharma, P., Hammers, H. J. and Escudier, B.; CheckMate 214 Investigators (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277-1290.
DOI
|
| 56 |
Klinger, M., Zugmaier, G., Nagele, V., Goebeler, M. E., Brandl, C., Stelljes, M., Lassmann, H., von Stackelberg, A., Bargou, R. C. and Kufer, P. (2020) Adhesion of T cells to endothelial cells facilitates blinatumomab-associated neurologic adverse events. Cancer Res. 80, 91-101.
DOI
|
| 57 |
Loffler, A., Kufer, P., Lutterbuse, R., Zettl, F., Daniel, P. T., Schwenkenbecher, J. M., Riethmuller, G., Dorken, B. and Bargou, R. C. (2000) A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95, 2098-2103.
DOI
|
| 58 |
Zhao, J., Zhao, J. and Perlman, S. (2012) Differential effects of IL-12 on Tregs and non-Treg T cells: roles of IFN-gamma, IL-2 and IL-2R. PLoS ONE 7, e46241.
DOI
|
| 59 |
Topp, M. S., Duell, J., Zugmaier, G., Attal, M., Moreau, P., Langer, C., Kronke, J., Facon, T., Salnikov, A. V., Lesley, R., Beutner, K., Kalabus, J., Rasmussen, E., Riemann, K., Minella, A. C., Munzert, G. and Einsele, H. (2020) Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J. Clin. Oncol. 38, 775-783.
DOI
|
| 60 |
D'Angelo, S. P., Melchiori, L., Merchant, M. S., Bernstein, D., Glod, J., Kaplan, R., Grupp, S., Tap, W. D., Chagin, K., Binder, G. K., Basu, S., Lowther, D. E., Wang, R., Bath, N., Tipping, A., Betts, G., Ramachandran, I., Navenot, J. M., Zhang, H., Wells, D. K., Van Winkle, E., Kari, G., Trivedi, T., Holdich, T., Pandite, L., Amado, R. and Mackall, C. L. (2018) Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 (c259) T cells in synovial sarcoma. Cancer Discov. 8, 944-957.
DOI
|
| 61 |
Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M. and van Hall, T. (2016) The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr. Opin. Immunol. 39, 44-51.
DOI
|
| 62 |
Gong, J., Chehrazi-Raffle, A., Reddi, S. and Salgia, R. (2018) Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J. Immunother. Cancer 6, 8.
|
| 63 |
Mhawech-Fauceglia, P., Zhang, S., Terracciano, L., Sauter, G., Chadhuri, A., Herrmann, F. R. and Penetrante, R. (2007) Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutipletumour tissue microarray technique. Histopathology 50, 472-483.
DOI
|
| 64 |
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T. T., Berman, D. M. and Wolchok, J. D. (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33, 1889-1894.
DOI
|
| 65 |
Fecci, P. E., Ochiai, H., Mitchell, D. A., Grossi, P. M., Sweeney, A. E., Archer, G. E., Cummings, T., Allison, J. P., Bigner, D. D. and Sampson, J. H. (2007) Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin. Cancer Res. 13, 2158-2167.
DOI
|
| 66 |
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Iglesias Docampo, L. C., Haddad, R., Rordorf, T., Kiyota, N., Tahara, M., Monga, M., Lynch, M., Geese, W. J., Kopit, J., Shaw, J. W. and Gillison, M. L. (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856-1867.
DOI
|
| 67 |
Gilboa, E. (1999) The makings of a tumor rejection antigen. Immunity 11, 263-270.
DOI
|
| 68 |
Cohen, E. E. W., Soulieres, D., Le Tourneau, C., Dinis, J., Licitra, L., Ahn, M. J., Soria, A., Machiels, J. P., Mach, N., Mehra, R., Burtness, B., Zhang, P., Cheng, J., Swaby, R. F. and Harrington, K. J.; KEYNOTE-040 investigators (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 393, 156-167.
DOI
|
| 69 |
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., Padera, R., Jaklitsch, M. T., Shankar, S., Chen, T. C., Korman, A., Allison, J. P. and Dranoff, G. (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. U.S.A. 100, 4712-4717.
DOI
|
| 70 |
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbe, C., Peschel, C., Quirt, I., Clark, J. I., Wolchok, J. D., Weber, J. S., Tian, J., Yellin, M. J., Nichol, G. M., Hoos, A. and Urba, W. J. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
DOI
|
| 71 |
Miyoshi, Y., Ando, A., Egawa, C., Taguchi, T., Tamaki, Y., Tamaki, H., Sugiyama, H. and Noguchi, S. (2002) High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin. Cancer Res. 8, 1167-1171.
|
| 72 |
Mullard, A. (2021) FDA approves first BCMA-targeted CAR-T cell therapy. Nat. Rev. Drug Discov. 20, 332.
|
| 73 |
Nair-Gupta, P., Diem, M., Reeves, D., Wang, W., Schulingkamp, R., Sproesser, K., Mattson, B., Heidrich, B., Mendonca, M., Joseph, J., Sendecki, J., Foulk, B., Chu, G., Fink, D., Jiao, Q., Wu, S. J., Packman, K., Elsayed, Y., Attar, R. and Gaudet, F. (2020) A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia. Blood Adv. 4, 906-919.
DOI
|
| 74 |
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Locke, F. L., Lin, Y., Jain, N., Daver, N., Gulbis, A. M., Adkins, S., Rezvani, K., Hwu, P. and Shpall, E. J. (2018) Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat. Rev. Clin. Oncol. 15, 218.
DOI
|
| 75 |
Bubenik, J. (2003) Tumour MHC class I downregulation and immunotherapy (review). Oncol. Rep. 10, 2005-2008.
|
| 76 |
Carpenter, R. O., Evbuomwan, M. O., Pittaluga, S., Rose, J. J., Raffeld, M., Yang, S., Gress, R. E., Hakim, F. T. and Kochenderfer, J. N. (2013) B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 19, 2048-2060.
DOI
|
| 77 |
Lu, Y., Parker, L., Lu, T., Zheng, Z., Yao, X., Robbins, P. F., van der Bruggen, P., Klebanoff, C. A., Hinrichs, C. S., Goff, S., Sherry, R., Kammula, U., Yang, J. C. and Rosenberg, S. A. (2015) A Phase I study of an HLA-DPB1*0401-restricted T cell receptor targeting MAGE-A3 for patients with metastatic cancers. J. Immunother. Cancer 3, P158.
DOI
|
| 78 |
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., Borquez-Ojeda, O., Qu, J., Wasielewska, T., He, Q., Bernal, Y., Rijo, I. V., Hedvat, C., Kobos, R., Curran, K., Steinherz, P., Jurcic, J., Rosenblat, T., Maslak, P., Frattini, M. and Sadelain, M. (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38.
DOI
|
| 79 |
Brudno, J. N. and Kochenderfer, J. N. (2016) Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127, 3321-3330.
DOI
|
| 80 |
Campbell, C. E., Kuriyan, N. P., Rackley, R. R., Caulfield, M. J., Tubbs, R., Finke, J. and Williams, B. R. (1998) Constitutive expression of the Wilms tumor suppressor gene (WT1) in renal cell carcinoma. Int. J. Cancer 78, 182-188.
DOI
|
| 81 |
Lynn, R. C., Weber, E. W., Sotillo, E., Gennert, D., Xu, P., Good, Z., Anbunathan, H., Lattin, J., Jones, R., Tieu, V., Nagaraja, S., Granja, J., de Bourcy, C. F. A., Majzner, R., Satpathy, A. T., Quake, S. R., Monje, M., Chang, H. Y. and Mackall, C. L. (2019) c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293-300.
DOI
|
| 82 |
Mangsbo, S. M., Sandin, L. C., Anger, K., Korman, A. J., Loskog, A. and Totterman, T. H. (2010) Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J. Immunother. 33, 225-235.
DOI
|
| 83 |
Correnti, C. E., Laszlo, G. S., de van der Schueren, W. J, Godwin, C. D., Bandaranayake, A., Busch, M. A., Gudgeon, C. J., Bates, O. M., Olson, J. M., Mehlin, C. and Walter, R. B. (2018) Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 costimulation. Leukemia 32, 1239-1243.
DOI
|
| 84 |
Carreno, B. M. and Collins, M. (2002) The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20, 29-53.
DOI
|
| 85 |
Chen, D. S. and Mellman, I. (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1-10.
DOI
|
| 86 |
Chow, M. T., Moller, A. and Smyth, M. J. (2012) Inflammation and immune surveillance in cancer. Semin. Cancer Biol. 22, 23-32.
DOI
|
| 87 |
Daver, N., Alotaibi, A. S., Bucklein, V. and Subklewe, M. (2021) T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia 35, 1843-1863.
DOI
|
| 88 |
Decker, W. K. and Safdar, A. (2009) Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited. Cytokine Growth Factor Rev. 20, 271-281.
DOI
|
| 89 |
Viardot, A., Goebeler, M. E., Hess, G., Neumann, S., Pfreundschuh, M., Adrian, N., Zettl, F., Libicher, M., Sayehli, C., Stieglmaier, J., Zhang, A., Nagorsen, D. and Bargou, R. C. (2016) Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood 127, 1410-1416.
DOI
|
| 90 |
Wilkie, S., Burbridge, S. E., Chiapero-Stanke, L., Pereira, A. C., Cleary, S., van der Stegen, S. J., Spicer, J. F., Davies, D. M. and Maher, J. (2010) Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J. Biol. Chem. 285, 25538-25544.
DOI
|
| 91 |
Kumar, V., Chaudhary, N., Garg, M., Floudas, C. S., Soni, P. and Chandra, A. B. (2017) Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front. Pharmacol. 8, 49.
DOI
|
| 92 |
Chandran, S. S. and Klebanoff, C. A. (2019) T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance. Immunol. Rev. 290, 127-147.
DOI
|
| 93 |
Costa, L. J., Wong, S. W., Bermudez, A., de la Rubia, J., Mateos, M., Ocio, E. M., Rodriguez-Otero, P., San-Miguel, J., Li, S., Sarmiento, R., Lardelli, P., Gaudy, A., Boss, I., Kelly, L. M., Burgess, M. R., Hege, K. and Bensinger, W. I. (2019) First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial. Blood 134(Supplement_1), 143.
DOI
|
| 94 |
Herbst, R. S., Baas, P., Kim, D. W., Felip, E., Perez-Gracia, J. L., Han, J. Y., Molina, J., Kim, J. H., Arvis, C. D., Ahn, M. J., Majem, M., Fidler, M. J., de Castro, G., Garrido, M., Lubiniecki, G. M., Shentu, Y., Im, E., Dolled-Filhart, M. and Garon, E. B. (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540-1550.
DOI
|
| 95 |
Huang, J., Brameshuber, M., Zeng, X., Xie, J., Li, Q. J., Chien, Y. H., Valitutti, S. and Davis, M. M. (2013) A single peptide-major histocompatibility complex ligand triggers digital cytokine secretion in CD4(+) T cells. Immunity 39, 846-857.
DOI
|
| 96 |
Thakur, A., Huang, M. and Lum, L. G. (2018) Bispecific antibody based therapeutics: strengths and challenges. Blood Rev. 32, 339-347.
DOI
|
| 97 |
Harrison, S. J., Minnema, M. C., Lee, H. C., Spencer, A., Kapoor, P., Madduri, D., Larsen, J., Ailawadhi, S., Kaufman, J. L., Raab, M. S., Hari, P., Iida, S., Vij, R., Davies, F. E., Lesley, R., Upreti, V. V., Yang, Z., Sharma, A., Minella, A. and Lentzsch, S. (2020) A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE® (bispecific T-cell engager) molecule, in relapsed/refractory (RR) multiple myeloma (MM). Blood 136, 28-29.
|
| 98 |
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., Tamada, K. and Chen, L. (2005) Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65, 1089-1096.
DOI
|
| 99 |
Hoffmann, M. M. and Slansky, J. E. (2020) T-cell receptor affinity in the age of cancer immunotherapy. Mol. Carcinog. 59, 862-870.
DOI
|
| 100 |
Kontermann, R. E. and Brinkmann, U. (2015) Bispecific antibodies. Drug Discov. Today 20, 838-847.
DOI
|
| 101 |
Yang, Y. F., Zou, J. P., Mu, J., Wijesuriya, R., Ono, S., Walunas, T., Bluestone, J., Fujiwara, H. and Hamaoka, T. (1997) Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res. 57, 4036-4041.
|
| 102 |
Wang, T. T. and Ravetch, J. V. (2019) Functional diversification of IgGs through Fc glycosylation. J. Clin. Invest. 129, 3492-3498.
DOI
|
| 103 |
Lorenczewski, G., Friedrich, M., Kischel, R., Dahlhoff, C., Anlahr, J., Balazs, M., Rock, D., Boyle, M. C., Goldstein, R., Coxon, A. and Chapman-Arvedson, T. (2017) Generation of a half-life extended anti-CD19 BiTE® antibody construct compatible with once-weekly dosing for treatment of CD19-positive malignancies. Blood 130, 2815.
|
| 104 |
Malik-Chaudhry, H. K., Prabhakar, K., Ugamraj, H. S., Boudreau, A. A., Buelow, B., Dang, K., Davison, L. M., Harris, K. E., Jorgensen, B., Ogana, H., Pham, D., Schellenberger, U., Van Schooten, W., Buelow, R., Iyer, S., Trinklein, N. D. and Rangaswamy, U. S. (2021) TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL. mAbs 13, 1890411.
DOI
|
| 105 |
Shimabukuro-Vornhagen, A., Godel, P., Subklewe, M., Stemmler, H. J., Schlosser, H. A., Schlaak, M., Kochanek, M., Boll, B. and von Bergwelt-Baildon, M. S. (2018) Cytokine release syndrome. J. Immunother. Cancer 6, 56.
DOI
|
| 106 |
Strome, S. E., Dong, H., Tamura, H., Voss, S. G., Flies, D. B., Tamada, K., Salomao, D., Cheville, J., Hirano, F., Lin, W., Kasperbauer, J. L., Ballman, K. V. and Chen, L. (2003) B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 63, 6501-6505.
|
| 107 |
Sugita, Y., Wada, H., Fujita, S., Nakata, T., Sato, S., Noguchi, Y., Jungbluth, A. A., Yamaguchi, M., Chen, Y. T., Stockert, E., Gnjatic, S., Williamson, B., Scanlan, M. J., Ono, T., Sakita, I., Yasui, M., Miyoshi, Y., Tamaki, Y., Matsuura, N., Noguchi, S., Old, L. J., Nakayama, E. and Monden, M. (2004) NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res. 64, 2199-2204.
DOI
|
| 108 |
Turley, S. J., Cremasco, V. and Astarita, J. L. (2015) Immunological hallmarks of stromal cells in the tumour microenvironment. Nat. Rev. Immunol. 15, 669-682.
DOI
|
webmaster
